These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 29040991)

  • 1. Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):583-588. PubMed ID: 29040991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Ida H; Sakurai T; Kitano M; Nishida N; Kudo M
    Dig Dis; 2016; 34(6):671-678. PubMed ID: 27750236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Kitano M; Nishida N; Kudo M
    Oncology; 2015; 89 Suppl 2():47-52. PubMed ID: 26584036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).
    Kudo M; Arizumi T; Ueshima K; Sakurai T; Kitano M; Nishida N
    Dig Dis; 2015 Oct; 33(6):751-8. PubMed ID: 26488473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma.
    Wang JH; Kee KM; Lin CY; Hung CH; Chen CH; Lee CM; Lu SN
    J Gastroenterol Hepatol; 2015 Feb; 30(2):358-63. PubMed ID: 25088668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification.
    Yamamoto M; Kobayashi T; Hashimoto M; Kuroda S; Kawaoka T; Aikata H; Chayama K; Ohdan H
    BMC Cancer; 2021 Jun; 21(1):668. PubMed ID: 34090354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
    Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
    Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
    Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Kim JH; Shim JH; Lee HC; Sung KB; Ko HK; Ko GY; Gwon DI; Kim JW; Lim YS; Park SH
    Liver Int; 2017 Dec; 37(12):1861-1868. PubMed ID: 28581250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma.
    Hu KS; Tang B; Yuan J; Lu SX; Li M; Chen RX; Zhang L; Ren ZG; Yin X
    J Gastroenterol Hepatol; 2019 Nov; 34(11):1984-1991. PubMed ID: 30932246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
    AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
    Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
    Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers.
    Kimura H; Ohkawa K; Miyazaki M; Sakakibara M; Imanaka K; Tamura T; Sueyoshi H; Takada R; Fukutake N; Uehara H; Ashida R; Ioka T; Nakazawa T; Nakanishi K; Katayama K
    Hepatol Int; 2017 Jan; 11(1):105-114. PubMed ID: 27766479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
    Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
    Jun CH; Yoon JH; Cho E; Shin SS; Cho SB; Kim HJ; Park CH; Kim HS; Choi SK; Rew JS
    Medicine (Baltimore); 2017 Apr; 96(17):e6745. PubMed ID: 28445298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Liver Cancer; 2017 Jun; 6(3):227-235. PubMed ID: 28626733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.